
A new prospective study challenges previous assumptions about the risk of liver fibrosis in patients treated with methotrexate. The study indicates that the risk may have been overestimated and suggests a reevaluation of the intensive strategies and screening tools used to monitor liver fibrosis in patients on methotrexate.
Like
Save
Share